| __timestamp | MannKind Corporation | Vericel Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 79383000 | 13774000 |
| Thursday, January 1, 2015 | 108402000 | 22479000 |
| Friday, January 1, 2016 | 46928000 | 27388000 |
| Sunday, January 1, 2017 | 74959000 | 35610000 |
| Monday, January 1, 2018 | 79716000 | 49007000 |
| Tuesday, January 1, 2019 | 74669000 | 61139000 |
| Wednesday, January 1, 2020 | 59040000 | 68836000 |
| Friday, January 1, 2021 | 77417000 | 97592000 |
| Saturday, January 1, 2022 | 91473000 | 106903000 |
| Sunday, January 1, 2023 | 94314000 | 120998000 |
Unlocking the unknown
In the dynamic world of biotechnology, understanding financial trends is crucial. Over the past decade, Vericel Corporation and MannKind Corporation have showcased distinct patterns in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, MannKind's SG&A expenses fluctuated, peaking in 2015 with a 38% increase from the previous year, before stabilizing around 94 million in 2023. In contrast, Vericel's SG&A expenses have shown a consistent upward trajectory, growing nearly ninefold from 2014 to 2023. This growth reflects Vericel's strategic investments in expanding its market presence and operational capabilities. By 2023, Vericel's SG&A expenses surpassed MannKind's by approximately 28%, highlighting its aggressive expansion strategy. These trends offer a window into the strategic priorities of these companies, with Vericel focusing on growth and MannKind maintaining a more conservative approach.
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and Vericel Corporation
Who Optimizes SG&A Costs Better? Novo Nordisk A/S or MannKind Corporation
Operational Costs Compared: SG&A Analysis of Teva Pharmaceutical Industries Limited and Vericel Corporation
SG&A Efficiency Analysis: Comparing Viatris Inc. and MannKind Corporation
Dr. Reddy's Laboratories Limited and Vericel Corporation: SG&A Spending Patterns Compared
Dr. Reddy's Laboratories Limited and MannKind Corporation: SG&A Spending Patterns Compared
Research and Development Investment: Vericel Corporation vs MannKind Corporation
Selling, General, and Administrative Costs: Vericel Corporation vs Dynavax Technologies Corporation
Comparing SG&A Expenses: Vericel Corporation vs Wave Life Sciences Ltd. Trends and Insights
Breaking Down SG&A Expenses: Vericel Corporation vs Agios Pharmaceuticals, Inc.
Vericel Corporation vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends
MannKind Corporation and Novavax, Inc.: SG&A Spending Patterns Compared